Open Treatment of Obsessive-Compulsive Disorder with Venlafaxine: A Series of Ten Cases

Journal of Clinical Psychopharmacology

Volumn 16, Issue 1, 1996, Pages 81-84

  Rauch, Scott L ^a   O'Sullivan, Richard L ^a   Jenike, Michael A ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CYCLOHEXANOL DERIVATIVE; VENLAFAXINE;

ADULT; AGED; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; LETTER; MALE; OBSESSIVE COMPULSIVE DISORDER; PSYCHOLOGICAL ASPECT;

ADULT; AGED; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CYCLOHEXANOLS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; OBSESSIVE-COMPULSIVE DISORDER;

EID: 0030074946     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/00004714-199602000-00017     Document Type: Letter

References (11)

1. Jenike MA. Obsessive-compulsive disorder: efficacy of specific treatments as assessed by controlled trials. Psychopharmacol Bull 1993;29:487-99.
2. Muth EA, Haskins JT, Moye JA, Husbands GEM, Neilsen ST, Sigg EB. Antidepressant biochemical profile of the novel tricyclic compound WY-45,030, an ethyl cyclohexanol derivative. Biochem Pharmacol 1986;35:493-7.
3. Montgomery SA. Venlafaxine. A new dimension in antidepressant pharmacotherapy. J Clin Psychiatry 1993;54:119-26.
4. Zajecka JM, Fawcett J, Guy C. Coexisting major depression and obsessive-compulsive disorder treated with venlafaxine (letter). J Clin Psychopharmacol 1990;10:152-3.
5. Yaryura-Tobias JA, Neziroglu FA, McKay DR. The action of venlafaxine on obsessive-compulsive disorder (abstract). Biol Psychiatry 1994;35:737.
6. Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann R, Hill C, Henninger GR, Charney DS. The Yale-Brown Obsessive Compulsive Scale (YBOCS): Part I. Development, use, and reliability. Arch Gen Psychiatry 1989;46:1006-11.
7. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561-71.
8. Jenike MA, Hyman S, Baer L, Holland A, Minichiello WE, Buttolph L, Summergrad P, Seymour R, Ricciardi J. A controlled trial of fluvoxamine in obsessive-compulsive disorder: implications for a serotonergic theory. Am J Psychiatry 1990;147:1209-15.
9. Keuthen NJ, Cyr P, Ricciardi JA, Minichiello WE, Buttolph ML, Jenike MA. Medication withdrawal symptoms in obsessive-compulsive disorder patients treated with paroxetine. J Clin Psychopharmacol 1994;14:206-7.
10. Barr LC, Goodman WK, Price LH. Physical symptoms associated with paroxetine discontinuation. Am J Psychiatry 1994;151:289.
11. Rasmussen SA, Goodman WK, Greist JH, Jenike MA, Kozak MJ, Liebowitz M, Robinson DG, White KL. Fluvoxamine in the treatment of obsessive-compulsive disorder: a multicenter double-blind placebo-controlled study in outpatients. Am J Psychiatry (in press).